(Q33854744)

29 July 2017

title

Safety of treatment with biologics for psoriasis in daily practice: 5-year data. (English)

1 reference

29 July 2017

P P M van Lümig

1

1 reference

29 July 2017

R J B Driessen

2

1 reference

29 July 2017

M A M Berends

3

1 reference

29 July 2017

J B M Boezeman

4

1 reference

29 July 2017

P C M van de Kerkhof

5

1 reference

29 July 2017

E M G J de Jong

6

1 reference

29 July 2017

publication date

24 March 2011

1 reference

Journal of the European Academy of Dermatology and Venereology

29 July 2017

published in

1 reference

29 July 2017

volume

26

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

283-291

1 reference

Treatments for psoriasis and the risk of malignancy

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

The Continuous Morbidity Registration Nijmegen: Background and history of a Dutch general practice database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04044.X

10.1111/J.1468-3083.2011.04044.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference